40 results about "HER2 Positive Breast Cancer" patented technology

The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.

Methods of treating patients having HER2-positive cancer are provided. Certain methods involve treatment of HER2 positive breast cancer using a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab or with trastuzumab emtansine. The treatment regimen may be used in various clinical settings, for example, for treatment in the neoadjuvant or metastatic setting.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and / or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The present invention relates to a nucleic acid aptamer specifically binding to HER2 polypeptide or HER2-positive tumor cells. The two ends of the aptamer can be modified by groups, and the groups are amino, amino, carboxyl, sulfhydryl, Any one or more of fluorescent molecules, cholesterol or polyethylene glycol; the base of the aptamer can be modified in any way, and the modification is any of thio, amino, fluoro, methoxy or carboxyl or multiple modifications. It also relates to the application of the above-mentioned nucleic acid aptamer in preparing preparations for detecting and / or treating HER2-positive breast cancer. The prepared preparation for treating HER2-positive breast cancer can selectively bind to HER2-positive breast cancer cells, but weakly bind to HER2-negative breast cancer cells.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and / or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The invention discloses application of aspirin and herceptin combination or synergy in oncotherapy, and relates to the technical field of oncotherapy. Relative to alone using of herceptin, aspirin is combined with the herceptin for medication, proliferation of HER2 positive tumor cells can be obviously restrained, and apoptosis of the HER2 positive tumor cells is promoted; and effect of anti-HER2 positive tumor of aspirin and herceptin combination for medication is better than effect of alone using of the herceptin. According to the application of aspirin and herceptin combination or synergy in oncotherapy, new application of the aspirin is discovered for the first time, and the aspirin helps to increase curative effect of the herceptin; and through the application of aspirin and herceptin combination or synergy in preparation of medicines used for treating tumors, theoretical basis is not only provided for anticancer effect of the aspirin in HER2 positive tumors, meanwhile, but also a new idea and a treatment mean are provided for treatment of tumors, especially HER2 positive tumors such as HER2 positive breast cancer or HER2 positive gastric cancer.

The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin TM ) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and / or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin TM ) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and / or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.